Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report)'s share price rose 7% on Tuesday . The company traded as high as $62.73 and last traded at $62.31. Approximately 236,021 shares traded hands during trading, a decline of 33% from the average daily volume of 351,951 shares. The stock had previously closed at $58.25.
Wall Street Analyst Weigh In
IRON has been the topic of a number of analyst reports. Wells Fargo & Company initiated coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They set an "overweight" rating and a $75.00 target price on the stock. Raymond James raised shares of Disc Medicine from an "outperform" rating to a "strong-buy" rating and increased their price target for the stock from $66.00 to $110.00 in a report on Monday. Jefferies Financial Group assumed coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They issued a "buy" rating and a $89.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $85.00 price target on shares of Disc Medicine in a report on Tuesday, October 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $70.00 price target on shares of Disc Medicine in a report on Tuesday. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $79.40.
View Our Latest Stock Report on Disc Medicine
Disc Medicine Stock Performance
The firm has a market cap of $1.91 billion, a PE ratio of -17.43 and a beta of 0.60. The company's 50-day simple moving average is $48.75 and its two-hundred day simple moving average is $42.93.
Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.08. On average, analysts expect that Disc Medicine, Inc. will post -4.09 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in IRON. Amalgamated Bank increased its stake in shares of Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company's stock worth $26,000 after acquiring an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock worth $54,000 after acquiring an additional 337 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Disc Medicine by 19.5% in the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company's stock worth $239,000 after acquiring an additional 793 shares in the last quarter. Bleakley Financial Group LLC increased its stake in shares of Disc Medicine by 23.0% in the 1st quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company's stock worth $285,000 after acquiring an additional 856 shares in the last quarter. Finally, TD Asset Management Inc increased its stake in shares of Disc Medicine by 3.7% in the 2nd quarter. TD Asset Management Inc now owns 40,732 shares of the company's stock worth $1,836,000 after acquiring an additional 1,468 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors.
Disc Medicine Company Profile
(
Get Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
